Blockchain Transaction Record
Glafabra Therapeutics Secures Exclusive Rights to Novel Vector for Treating Enzyme Deficiency Diseases.
The licensed technology improves the potency of cell gene therapies by increasing the transformation capacity of lentivirus vectors. Dramatic improvements in patient outcomes are expected from the resulting higher expression of therapeutic protein.
Exclusively at Newsworthy.ai — Newsworthy registers every press release distributed through this service on the blockchain so that we can provide verification services and make features such as the self-hosting of press releases available to our customers. The blockchain provides an immutable record of the press releases issued by this service. Immutability gives readers the assurance that the news they are reading has not been altered from the source document that this service distributed. We have shifted the Source of Truth to the blockchain for added protection.
Moving the Source of Truth to the blockchain improves transparency and increases trust between organizations submitting news and readers.
Key Takeaways (TLDR)
- Glafabra Therapeutics achieves higher vector efficiency for potent cellular therapy in genetic diseases.
- Patients report significant health improvements after LV gene therapy for Fabry disease.
- Glafabra plans to expand to the USA, offering innovative enzyme deficiency disease treatments globally.
| Blockchain | Details |
|---|---|
| Chain | polygon-main |
| Transaction ID | 0x029095205a238d2541545b80ac177c13435999b68461c6cb405794df2aee7fdc |
| Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
| NWAI Digital Fingerprint | 1400-fe44fac9afebca21ab058d6f59d15980 |
| Registration Timestamp | 2025-01-13T22:46:00+00:00 |
Other Recent Blockchain Registered News for Glafabra Therapeutics, Inc.
- Glafabra Therapeutics and University of Utah Announce Intent to Collaborate on Clinical Investigation for Fabry Disease Salt Lake City, Utah (Newsworthy.ai) Saturday Jan 11, 2025 @ 7:00 AM MST — Glafabra Therapeutics enters into an LOI agreement with the University of Utah to collaborate with the Utah Data Coordinating Center and The Cell Therapy and Regenerative Medicine Program. Clinical trials are being planned to test a novel LV gene therapy as a treatment option for patients with Fabry Disease.